Guenther Dermatology Research Centre

Recent papers from Guenther Dermatology Research Centre

1. 52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trialJournal of the European Academy of Dermatology and Venereology · 2026
2. Constructive Organizational Geometry: From Configuration Structure to Transport, Connection, and Curvature2026
3. A Public-Data Mechanism Lock for the MMA-DMF vac+ / Majorana-Linked UHECR Branch2026
4. G2‐PASE: A Novel, Rapid, and Reliable Measure of Plaque Psoriasis SeverityJEADV Clinical Practice · 2026
5. Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic DermatitisAllergy · 2025
6. Results from the 32‐week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJournal of the European Academy of Dermatology and Venereology · 2025
7. Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic DermatitisDermatology and Therapy · 2025
8. Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensusExpert Review of Vaccines · 2025
9. Combined and Hybrid Treatments of Hyaluronic Acid (HA) and Calcium Hydroxylapatite (CaHA): A Systematic Review of Mechanisms of Action, Aesthetic Effectiveness, Satisfaction, and Safety ProfileAesthetic Plastic Surgery · 2025
10. Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque PsoriasisDermatology and Therapy · 2024
11. 544 - Cost-per-responder analysis of tralokinumab versus dupilumab in patients with moderate-to-severe atopic dermatitis in the US and CanadaBritish Journal of Dermatology · 2024
12. Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and CanadaSKIN The Journal of Cutaneous Medicine · 2024
13. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology · 2023
14. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Journal of Cutaneous Medicine and Surgery · 2023
15. Value in psoriasis (IRIS) trial: implementing value-based healthcare in psoriasis management – a 1-year prospective clinical study to evaluate feasibility and value creationBMJ Open · 2023
16. Terahertz imaging of human skin pathologies using laser feedback interferometry with quantum cascade lasersBiomedical Optics Express · 2023
17. The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivityJournal of the European Academy of Dermatology and Venereology · 2023
18. Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With AdalimumabJournal of Cutaneous Medicine and Surgery · 2022
19. Impact of fixed‐dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52‐week randomized, double‐blind, PSO‐LONG trialJournal of the European Academy of Dermatology and Venereology · 2022
20. Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial PilotBlockchain in Healthcare Today · 2021